 (Heart 1996;75:94-97) 
Disease phenotypes
The relations between hypertrophic cardiomyopathy and the cardiac phenotype of Noonan syndrome and primary (non-infiltrative) restrictive Case report The patient presented at age 14 years with cough and dyspnoea on exertion. There was no family history of heart disease and she had two healthy siblings. Birth and development had been normal except for short stature. Menarche was at age 11 years.
She was below the fifth centile for height (1 52 m) with features of Noonan syndrome, consisting of a webbed neck, low-set ears, ptosis, prominent epicanthal folds, downward slanting palpebral fissures, micrognathia, pectus excavatum, wide-spaced nipples, and cubitus valgus. Psychological assessment showed no intellectual deficit. She was not cyanosed and did not have clubbed digits. Blood pressure was 110/70 mm Hg. Venous pressure was not raised. Right and left ventricular impulses were prominent. There was a fourth heart sound and a soft pulmonary systolic murmur.
The electrocardiogram showed sinus rhythm, partial right bundle branch block, left atrial hypertrophy, and T wave inversion in leads V3-V6. The chest x ray showed a cardiothoracic ratio of 044 but a large left atrium. The echocardiogram showed no valve abnormality and a mildly dilated left atrium (43 mm diameter). Left ventricular diameters (end diastolic 37 mm, end systolic 20 mm) and wall thicknesses (septum 12 mm, posterior wall 10 mm) were normal. There were no features of hypertrophic cardiomyopathy. Lung infiltration or abnormal fibrosis.
She had pregnancies at ages 17 and 21 years. Both deliveries were by emergency caesarean section because of antepartum haemorrhagge. On the first occasion Syntometrine (ergometrine/oxytocin) was given and caused pulmonary oedema. Since then she has had increasingly severe tricuspid regurgitation and dyspnoea on exertion and palpitation. Repeat echocardiograms showed that the left atrial diameter was increasing but the left ventricular dimensions remained normal.
Her third pregnancy (age 24 years) was managed with elective caesarean section. Perioperatively she had paroxysmal atrial fibrillation and a femoral artery embolus. This was treated by embolectomy and anticoagulation. Since then she has remained on warfarin and antiarrhythmic drugs. Amiodarone caused thyrotoxicosis. Currently she takes digoxin and atenolol.
Her fourth pregnancy (age 25) was terminated on medical grounds. The aborted fetus (15 weeks) appeared normal and there was no structural or histological abnormality in the heart. The same year she had a detailed neurological examination and electromyography. They excluded a skeletal myopathy. Ophthalmological examination was also normal.
Currently (aged 28) she has mild dyspnoea on exertion and atrial arrhythmias. She '6 Variations in expression between generations may be the result of other inherited or acquired factors interacting in individuals with the same genotype but they may also be the result of changes in the mutant gene itself. Certainly in other inherited cardiomyopathies differences between generations result from further repeat sequence expansion during mitosis or meiosis causing more florid manifestations (so called "anticipation") or normalisation of the mutant sequence ("reverse mutation").'718 A Noonan syndrome gene has recently been located at chromosome 12q22-qter3 in several families by linkage analysis. In one family, haplotype analysis showed non-linkage, indicating that for Noonan syndrome there is also genetic heterogeneity. The locus of the identified Noonan syndrome gene does not correspond with any of the known genetic loci of hypertrophic cardiomyopathy. It is not situated near the gene responsible for neurofibromatosis 1 and Watson syndrome on chromosome 17 or neurofibrosis 2 on chromosome 22."9 One patient with some characteristics of Noonan syndrome also had some features of right ventricular dysplasia,9 but a gene for right ventricular dysplasia maps to chromosome 14q23-24.2' Paradoxically, a Holt-Oram syndrome gene, which has a dissimilar phenotype, has been localised to the same region as the Noonan syndrome gene (1 2q22-qter). 21 Primary restrictive cardiomyopathy seems to be dominantly inherited in some families,6 "1 but the responsible gene 
Acquired factors
The observation that similar phenotypes can be the result of abnormalities of a number of widely separate genes should initiate a search for common mechanisms by which they exert similar effects on myocyte hypertrophy and alignment.
Two of the three patients previously described with Noonan syndrome and restrictive cardiomyopathy had hyperthyroisism.8 Others have reported a 30% incidence of autoimmune thyroid autoantibodies in patients with Noonan syndrome, none of whom had overt thyroid disease.5 The patient we describe was hyperthyroid when receiving amiodarone. This may indicate predisposition to autoimmune thyroid disease, which may be familial.
Hypertrophic cardiomyopathy is also associated with hyperthyroidism,22 but the association may not be the result of genetic linkage. A cardiomyopathy with features of hypertrophic cardiomyopathy has been described in association with hypothyroidism and the cardiac abnormalities returned to normal when the patients became euthyroid.2' 24 When Noonan syndrome occurs in families, maternal transmission is far more common than paternal transmission. Influence of intrauterine events on expression of a genetic disease is a possible reason, but there are others. Abnormalities associated with mitochondrial DNA mutations are maternally transmitted and can be associated with a hypertrophic cardiomyopathy.15 Genomic imprinting causing differential expression of maternal and paternal DNA may result from differential methylation of maternal and paternal DNA,29 but a simpler explanation is that when genetic abnormalities result from repeat sequence amplification, the ovum will be large enough to accomodate a greater sequence amplification than the sperm, so that maternally transmitted disease will be more florid. This is the case in myotonic dystrophy, which includes a cardiomyopathy and a skeletal myodystrophy and results from increased trinucleotide repeats at chromosome 19q13.3.
Other mechanisms by which genetic and acquired factors can affect myocyte hypertrophy and disarray include expression of proto-oncogenes and influence of growth factors such as the local renin-angiotensin system.'0
